Navigation Links
Transgenomic Reports Third Quarter Financial Results
Date:11/15/2010

urrent views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.Transgenomic, Inc. and SubsidiarySummary Financial ResultsUnaudited Condensed Consolidated Statements of Operations(dollars in thousands except per share data)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2010200920102009NET SALES$  4,419

$  5,046

$  14,956

$  15,508COST OF GOODS SOLD2,402

2,293

7,568

7,291Gross profit

2,017

2,753

7,388

8,217OPERATING EXPENSES:Selling, general and administrative

2,159

2,215

7,623

7,922Research and development

613

938

1,952

2,468Restructuring charges

72

72

—2,844

3,153

9,647

10,390LOSS FROM OPERATIONS(827)

(400)

(2,259)

(2,173)OTHER INCOME (EXPENSE):Interest income

1

1

14Other, net

(1)

(4)—
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
2. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
3. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
4. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
5. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
6. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
7. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
8. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
9. Transgenomic, Inc. Reports Third Quarter 2009 Results
10. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
11. Transgenomic, Inc. Reports Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... NEW YORK -- Water vapor and clouds are the ... atmosphere-ocean climate modeling study shows that the planet,s temperature ... The study, conducted by Andrew Lacis and ... in New York, examined the nature of Earth,s greenhouse ...
... University of British Columbia today welcomed the announcement of ... Health Research (CIHR) and Genome British Columbia for research ... led by UBC researchers Brett Finlay and Deborah Money, ... today in Toronto by federal Health Minister Leona Aglukkaq. ...
... Cancer Research congratulates 12 of its members on their election ... new members and five foreign associates. Considered among ... the award recognizes individuals who have demonstrated outstanding professional achievement ... medicine. "This is a great day for cancer ...
Cached Biology News:Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3The AACR congratulates its members elected to the Institute of Medicine 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: